Study of PD1 therapy on atypical moles in melanoma patients
Part of Brain & nervous system, Cancer, Genetic & congenital, Skin clinical trials.
This trial tests if an immunotherapy drug (anti-PD1) can change atypical (dysplastic) moles in people who have had melanoma. It may help understand how these drugs affect mole cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have at least two atypical moles that are 4 mm or larger.
- You must have had melanoma (skin cancer) and be a candidate for anti-PD1 therapy after surgery.
- You must be 18 or older and agree to use effective birth control if you could become pregnant.
- You cannot have a serious autoimmune disease or be on strong immune-suppressing medication.
- You cannot have had anti-PD1 therapy before or be on other cancer treatments now.
- You cannot have another active cancer besides melanoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial studies OH2 injection given directly into a melanoma tumor, combined with HX008, to see if it can shrink tumors after standard treatments—including PD-1—did not work. It may help people with advanced melanoma, especially when there is a reachable tumor for injection.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.